Head and neck cancer diagnostics market to grow by $6.3b by 2028

The sector is experiencing an upward trend in immunotherapy use.

The global head and neck cancer diagnostics market is expected to rise by $6.3b through 2028 at an estimated compound annual growth rate (CAGR) of 13.64, said Technavio.

The sector’s expansion is attributed to an increasing incidence of head and neck cancers and the growing emphasis on early detection.

Diagnostic techniques, such as MRI, CT, PET/CT, and chest imaging play a key role in identifying cancerous tumours.

In addition, genomic testing, tumour sequencing, and molecular profiling aid in the development of personalised treatment plans for individual patients.

Meanwhile, the market is witnessing a rise in the use of immunotherapy, also known as biological therapy.

The technique’s adoption is due to its capability of bolstering the body’s immune system to combat cancer cells.

Moreover, clinical trials for immunotherapies and targeted therapies are driving new treatment modes.

“The growing acceptance and success of immunotherapy in cancer treatment are driving the demand for accurate and efficient diagnostics to identify eligible patients,” the report said.